Tiziana Life Sciences (TLSA) announced that its grant application to the ALS Association has been approved for funding. The grant is awarded as part of the Hoffman ALS Clinical Trial Awards Program and is titled “Modulation of ALS neuroinflammation by nasal anti-CD3 monoclonal Antibody”. The Association’s grant will fund a 20-patient clinical trial of two doses of Tiziana’s novel and patented therapeutic candidate, intranasal foralumab, aimed at evaluating the safety and early-stage parameters of disease improvement in Amyotrophic Lateral Sclerosis, ALS, also known as Lou Gehrig’s disease.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TLSA:
- Tiziana Life Sciences Highlights Advancements at BIO-Europe 2024
- Tiziana Life Sciences Announces $10 Million Share Offering
- Tiziana Life Sciences Reports Promising Obesity Therapy Results
- Tiziana Life Sciences announces results from ozempic, nasal anti-CD3 study
- Tiziana Life Sciences Plans Share Sale with Jefferies